{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T12:44:15Z","timestamp":1776689055137,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-025-01811-w","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T03:46:30Z","timestamp":1748058390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The comparison of outcomes between neoadjuvant novel and classical hormonal therapy in patients with locally advanced prostate cancer: a retrospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhen","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanjie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"1811_CR1","volume-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer","author":"PTD Cornford","year":"2024","unstructured":"Cornford PTD, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2024."},{"key":"1811_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-Based management. J Urol. 2022;208:10\u20138.","journal-title":"J Urol"},{"key":"1811_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/14737140.2021.1852932","volume":"21","author":"L Moris","year":"2021","unstructured":"Moris L, Devos G, Van den Broeck T, Milonas D, Albersen M, Berghen C, et al. Current and emerging therapies for localized high-risk prostate cancer. Expert Rev Anticancer Ther. 2021;21:267\u201382.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1811_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/JU.0000000000002250","volume":"207","author":"F Chierigo","year":"2022","unstructured":"Chierigo F, Wenzel M, W\u00fcrnschimmel C, Flammia RS, Horlemann B, Tian Z, et al. Survival after radical prostatectomy versus radiation therapy in High-Risk and very High-Risk prostate Cancer. J Urol. 2022;207:375\u201384.","journal-title":"J Urol"},{"key":"1811_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.urolonc.2014.11.018","volume":"33","author":"A Briganti","year":"2015","unstructured":"Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, et al. Natural history of surgically treated high-risk prostate cancer. Urologic Oncology: Seminars Original Investigations. 2015;33:163..e7-.e13.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"1811_CR6","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.1200\/JCO.2007.15.0441","volume":"26","author":"J Kollermann","year":"2008","unstructured":"Kollermann J, Weikert S, Schostak M, Kempkensteffen C, Kleinschmidt K, Rau T, et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncology: Official J Am Soc Clin Oncol. 2008;26:4928\u201333.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"1811_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/pros.10018","volume":"49","author":"FJ Bianco Jr","year":"2001","unstructured":"Bianco FJ Jr., Wood DP Jr., Gomes de Oliveira J, Nemeth JA, Beaman AA, Cher ML. Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate. 2001;49:235\u201342.","journal-title":"Prostate"},{"key":"1811_CR8","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1200\/JCO.1997.15.12.3451","volume":"15","author":"DP Wood Jr","year":"1997","unstructured":"Wood DP Jr., Banerjee M. Presence of Circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncology: Official J Am Soc Clin Oncol. 1997;15:3451\u20137.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"1811_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1464-410X.2009.08698.x","volume":"105","author":"DS Yee","year":"2010","unstructured":"Yee DS, Lowrance WT, Eastham JA, Maschino AC, Cronin AM, Rabbani F. Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. BJU Int. 2010;105:185\u201390.","journal-title":"BJU Int"},{"key":"1811_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","volume":"35","author":"MD Shelley","year":"2009","unstructured":"Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35:9\u201317.","journal-title":"Cancer Treat Rev"},{"key":"1811_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/01.ju.0000081404.98273.fd","volume":"170","author":"LH Klotz","year":"2003","unstructured":"Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170:791\u20134.","journal-title":"J Urol"},{"key":"1811_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1046\/j.1464-410X.2002.02982.x","volume":"90","author":"G Aus","year":"2002","unstructured":"Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002;90:561\u20136.","journal-title":"BJU Int"},{"key":"1811_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.2174\/1389450121666200621194409","volume":"22","author":"A Tafuri","year":"2021","unstructured":"Tafuri A, Cerruto MA, Antonelli A. Neoadjuvant strategies before radical prostatectomy for high risk prostate Cancer in the era of new hormonal agents. Curr Drug Targets. 2021;22:68\u201376.","journal-title":"Curr Drug Targets"},{"key":"1811_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41585-018-0017-x","volume":"15","author":"G Pignot","year":"2018","unstructured":"Pignot G, Maillet D, Gross E, Barthelemy P, Beauval J-B, Constans-Schlurmann F, et al. Systemic treatments for high-risk localized prostate cancer. Nat Reviews Urol. 2018;15:498\u2013510.","journal-title":"Nat Reviews Urol"},{"key":"1811_CR15","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","volume":"83","author":"G Devos","year":"2023","unstructured":"Devos G, Tosco L, Baldewijns M, Gevaert T, Goffin K, Petit V, et al. ARNEO: A randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for High-risk prostate Cancer. Eur Urol. 2023;83:508\u201318.","journal-title":"Eur Urol"},{"key":"1811_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/JU.0000000000001702","volume":"206","author":"RR McKay","year":"2021","unstructured":"McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R, et al. Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with High-Risk localized prostate Cancer. J Urol. 2021;206:80\u20137.","journal-title":"J Urol"},{"key":"1811_CR17","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","volume":"32","author":"M-E Taplin","year":"2014","unstructured":"Taplin M-E, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense Androgen-Deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized High-Risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32:3705\u201315.","journal-title":"J Clin Oncol"},{"key":"1811_CR18","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1200\/JCO.18.01777","volume":"37","author":"RR McKay","year":"2019","unstructured":"McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, et al. Evaluation of intense androgen deprivation before prostatectomy: A randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37:923\u201331.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"1811_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/JU.0000000000002803","volume":"208","author":"P Ravi","year":"2022","unstructured":"Ravi P, Kwak L, Xie W, Kelleher K, Acosta AM, McKay RR, et al. Neoadjuvant novel hormonal therapy followed by prostatectomy versus Up-Front prostatectomy for High-Risk prostate cancer: A comparative analysis. J Urol. 2022;208:838\u201345.","journal-title":"J Urol"},{"key":"1811_CR20","doi-asserted-by":"publisher","first-page":"1217303","DOI":"10.3389\/fphar.2023.1217303","volume":"14","author":"J Zhuang","year":"2023","unstructured":"Zhuang J, Wang Y, Zhang S, Fu Y, Huang H, Lyu X, et al. Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials. Front Pharmacol. 2023;14:1217303.","journal-title":"Front Pharmacol"},{"key":"1811_CR21","first-page":"676","volume":"45","author":"Pathological Expert Group of U, Male Reproductive System Disease of Chinese Pathology A","year":"2016","unstructured":"Pathological Expert Group of U, Male Reproductive System Disease of Chinese Pathology A. Consensus on specimen handling and pathologic diagnosis of prostatic carcinoma. Zhonghua Bing Li Xue Za zhi = Chin J Pathol. 2016;45:676\u201380.","journal-title":"Zhonghua Bing Li Xue Za zhi = Chin J Pathol"},{"key":"1811_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JU.0000000000001375","volume":"205","author":"WT Lowrance","year":"2021","unstructured":"Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA\/ASTRO\/SUO guideline PART I. J Urol. 2021;205:14\u201321.","journal-title":"J Urol"},{"key":"1811_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41391-022-00496-8","volume":"25","author":"LS Lee","year":"2022","unstructured":"Lee LS, Sim AYL, Ong CW, Yang X, Ng CCY, Liu W, et al. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:741\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1811_CR24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","volume":"73","author":"GP Paner","year":"2018","unstructured":"Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the Tumor-Node-Metastasis staging classification for urologic cancers. Eur Urol. 2018;73:560\u20139.","journal-title":"Eur Urol"},{"key":"1811_CR25","doi-asserted-by":"crossref","unstructured":"Rice MA, Malhotra SV, Stoyanova T, Second-Generation, Antiandrogens. From discovery to standard of care in castration resistant prostate Cancer. Front Oncol. 2019;9.","DOI":"10.3389\/fonc.2019.00801"},{"key":"1811_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/OAJU.S6573","volume":"2","author":"A Berruti","year":"2010","unstructured":"Berruti A, Vignani F, Russo L, Bertaglia V, Tullio M, Tucci M, et al. Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle. Open Access J Urol. 2010;2:109\u201324.","journal-title":"Open Access J Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01811-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01811-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01811-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T03:46:33Z","timestamp":1748058393000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01811-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1811"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01811-w","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Second Hospital of Tianjin Medical University, and the approval number is 2023003. All patients received informed consent regarding this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}